Clinical trial
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian…
NCT00275028 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00275028 |
|---|---|
| Title | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer |
| Official title | A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Epithelial Cancer, Stage I Ovarian Epithelial Cancer, Stage II Ovarian Epithelial Cancer |
| Intervention type | Drug |
| Interventions | cediranib maleate |
| Enrollment | 47 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2010 |
| Completion | Jan 1, 2011 |
| First posted | Jan 11, 2006 |
| Last update posted | Nov 9, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: